体外从造血干细胞生成自然杀伤细胞用于免疫治疗。
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
机构信息
Anthony Nolan Research Institute, and University College London, Royal Free Campus, London, UK.
出版信息
Cell Mol Immunol. 2012 Jul;9(4):310-20. doi: 10.1038/cmi.2012.17. Epub 2012 Jun 18.
Abstract
Natural killer (NK) cells are part of the innate immune system and are an alluring option for immunotherapy due to their ability to kill infected cells or cancer cells without prior sensitization. Throughout the past 20 years, different groups have been able to reproduce NK cell development in vitro, and NK cell ontogeny studies have provided the basis for the establishment of protocols to produce NK cells in vitro for immunotherapy. Here, we briefly discuss NK cell development and NK cell immunotherapy approaches. We review the factors needed for NK cell differentiation in vitro, which stem cell sources have been used, published protocols, challenges and future directions for Good Manufacturing Practice protocols.
摘要
自然杀伤 (NK) 细胞是先天免疫系统的一部分，由于其能够在无需预先致敏的情况下杀死感染细胞或癌细胞，因此成为免疫治疗的诱人选择。在过去的 20 年中，不同的研究小组已经能够在体外复制 NK 细胞的发育，而 NK 细胞个体发生的研究为建立用于免疫治疗的体外产生 NK 细胞的方案提供了基础。在这里，我们简要讨论 NK 细胞的发育和 NK 细胞免疫治疗方法。我们回顾了体外 NK 细胞分化所需的因素、已使用的干细胞来源、已发表的方案、面临的挑战以及良好生产规范方案的未来方向。
相似文献
1
Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
Cell Mol Immunol. 2012 Jul;9(4):310-20. doi: 10.1038/cmi.2012.17. Epub 2012 Jun 18.
2
Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells.
PLoS One. 2014 Jan 29;9(1):e87086. doi: 10.1371/journal.pone.0087086. eCollection 2014.
3
Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Cancer Immunol Immunother. 2016 Apr;65(4):477-84. doi: 10.1007/s00262-016-1792-y. Epub 2016 Jan 25.
4
High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
PLoS One. 2010 Feb 15;5(2):e9221. doi: 10.1371/journal.pone.0009221.
5
An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
Methods Mol Biol. 2019;2048:107-119. doi: 10.1007/978-1-4939-9728-2_12.
6
Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.
Immunol Res. 2017 Dec;65(6):1130-1138. doi: 10.1007/s12026-017-8955-6.
7
Potential therapeutic role of natural killer cells in cancer.
Expert Opin Biol Ther. 2007 Jan;7(1):17-29. doi: 10.1517/14712598.7.1.17.
8
NK cell-based cancer immunotherapy: from basic biology to clinical development.
J Hematol Oncol. 2021 Jan 6;14(1):7. doi: 10.1186/s13045-020-01014-w.
9
Targeting natural killer cells in cancer immunotherapy.
Nat Immunol. 2016 Aug 19;17(9):1025-36. doi: 10.1038/ni.3518.
10
Harnessing NK Cell Memory for Cancer Immunotherapy.
Trends Immunol. 2016 Dec;37(12):877-888. doi: 10.1016/j.it.2016.09.005. Epub 2016 Oct 21.
引用本文的文献
1
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.
Expert Rev Clin Immunol. 2024 Jul;20(7):745-763. doi: 10.1080/1744666X.2024.2349738. Epub 2024 May 14.
2
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Cells. 2024 Mar 5;13(5):451. doi: 10.3390/cells13050451.
3
Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.
Stem Cells Transl Med. 2024 Mar 15;13(3):230-242. doi: 10.1093/stcltm/szad087.
4
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.
Mol Cancer. 2023 Nov 28;22(1):189. doi: 10.1186/s12943-023-01873-0.
5
Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.
Hum Cell. 2023 Nov;36(6):1843-1864. doi: 10.1007/s13577-023-00948-w. Epub 2023 Jul 21.
6
Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy Products.
Biology (Basel). 2023 May 4;12(5):677. doi: 10.3390/biology12050677.
7
Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.
Front Immunol. 2023 Jan 11;13:1044946. doi: 10.3389/fimmu.2022.1044946. eCollection 2022.
8
Advancing cell-based cancer immunotherapy through stem cell engineering.
Cell Stem Cell. 2023 May 4;30(5):592-610. doi: 10.1016/j.stem.2023.02.009. Epub 2023 Mar 21.
9
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).
Int J Mol Sci. 2022 Nov 17;23(22):14255. doi: 10.3390/ijms232214255.
10
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model.
Sci Adv. 2022 Nov 25;8(47):eadd1187. doi: 10.1126/sciadv.add1187. Epub 2022 Nov 23.
本文引用的文献
1
Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells.
Leukemia. 2012 May;26(5):1149-52. doi: 10.1038/leu.2011.345. Epub 2011 Dec 6.
2
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26.
3
Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma.
Cancer Biother Radiopharm. 2011 Aug;26(4):503-10. doi: 10.1089/cbr.2011.0982. Epub 2011 Aug 3.
4
NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions.
Blood. 2011 Sep 8;118(10):2784-92. doi: 10.1182/blood-2011-04-347070. Epub 2011 Jul 14.
5
Different NK cell developmental events require different levels of IL-15 trans-presentation.
J Immunol. 2011 Aug 1;187(3):1212-21. doi: 10.4049/jimmunol.1100331. Epub 2011 Jun 29.
6
Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.
PLoS One. 2011;6(6):e20740. doi: 10.1371/journal.pone.0020740. Epub 2011 Jun 16.
7
CD56brightCD16+ NK cells: a functional intermediate stage of NK cell differentiation.
J Immunol. 2011 Jun 15;186(12):6753-61. doi: 10.4049/jimmunol.1100330. Epub 2011 May 9.
8
Interleukin 15 as a promising candidate for tumor immunotherapy.
Cytokine Growth Factor Rev. 2011 Apr;22(2):99-108. doi: 10.1016/j.cytogfr.2011.04.001. Epub 2011 Apr 29.
9
Ex vivo expansion of natural killer cells: a question of function.
Cytotherapy. 2011 Jul;13(6):767-8. doi: 10.3109/14653249.2011.563295. Epub 2011 Mar 7.
10
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
Zotero 插件